US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress

Past year was the high-water mark for product approvals and launches, but complete response letters remain a frequent occurrence. FDA’s ability to deliver on its promise of further clarity on transition products, interchangeability and indication carve-outs/carve-ins may take a hit from the ongoing partial government shutdown. On the legal side, look for more patent settlements with staggered entry dates and new antitrust scrutiny.

Last year saw a watershed in the US biosimilars space, with a record number of approvals and launches, new regulatory strategies employed by 351(k) applicants trying to get around patent issues, and new guidance for products that will make a sudden and dramatic shift from drug to biologic regulation in March 2020.

However, 2018 also saw a continuing spate of FDA complete response letters (CRLs) and an ongoing lack of clarity around...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics